European study seeks early blood signals of brain disease
An observational case-cohort study assembled blood data from 6,415 adults aged 35–80, with up to 30 years of follow-up, to investigate future disease risk.
Our read
AI & data- Studied:
- Cohort study of 6,415 initially non-diseased participants, up to 30 years (Multicenter)
- The catch:
- Lower sensitivity of health records likely misclassifies some Alzheimer's cases as non-cases
Editor of record: Boris Djordjevic · AgingResearch.News
European adults aged 35–80 at enrollment supplied blood samples for an observational case-cohort study involving 6,415 people, 64% of them women. Participants initially had none of the diseases being tracked: dementia, including Alzheimer’s disease; Parkinson’s disease; or amyotrophic lateral sclerosis, which damages nerves controlling movement.
The design combined a randomly selected group with additional participants who developed disease during follow-up. Researchers measured proteins, genetic variants and chemical tags on DNA in stored blood samples collected before disease onset. All three types of data were available for 4,127 participants. Analyses reproduced many known genetic and lifestyle risk links. The authors aim to combine these molecular measurements with medical and lifestyle information to identify blood signals that might predict future disease.
Why it matters
For brain diseases associated with aging, measurements taken before diagnosis offer a way to explore shared biological pathways and their links with lifestyle risk factors.
Caveats
Health records may have missed some dementia cases, while amyotrophic lateral sclerosis cases were identified only through death records. Participants came from five European countries and were mostly of European descent.
From the paper
- Participants
The EPIC4ND case-cohort comprises a total of 6415 participants aged 35–80 years at baseline who were recruited as part of the EPIC study in twelve centers across five countries.
Results, Description of the case-cohort and case ascertainment
- Follow-up
This population-based case-cohort study is unique in the ND field for its study design with the availability of pre-disease blood samples, an extensive follow-up period of up to 30 years, and the new, in-depth measurements of multi-layered molecular data.
Results, Comparison with other resources, strengths and limitations
Quoted word for word from the full text on link.springer.com.
- Resources: datasets, atlases and tools
- Dementia
- Alzheimer's disease
- Parkinson's disease
- Amyotrophic lateral sclerosis
- Humans
The paper
University of Münster; Imperial College London
European Journal of Epidemiology, Jul 22, 2026, Open access
Comments
Be the first to comment.